Indeed, Hakkim et al. showed in the German cohort that NET degradation activity was impaired in a subset of lupus patients because of the presence of DNase1 inhibitors or anti-NET antibodies, and NET non-degraders had significantly higher anti-dsDNA antibody titers than NET degraders23. Here, DNASE1 is linked to systemic lupus erythematosus.